Guide

FDA Enforcement Timeline: Major Actions on Peptides and Compounding

This guide traces the major regulatory actions the U.S. Food and Drug Administration has taken related to peptide compounding and the online peptide marketplace. The timeline begins with the 2013 Drug Quality and Security Act (DQSA), which established the modern framework for pharmacy compounding after a deadly meningitis outbreak traced to a compounding pharmacy. It follows the FDA's evolving enforcement posture through warning letters to peptide sellers, the GLP-1 shortage and compounded semaglutide debate, the 2026 Gram Peptides warning letter, and the July 2026 Pharmacy Compounding Advisory Committee meeting where multiple peptide bulk substances are under review. Each entry includes the date, the action taken, and why it matters for the peptide landscape.

November 2013: Drug Quality and Security Act (DQSA) Passed

Congress passed the Drug Quality and Security Act (DQSA) in response to the 2012 New England Compounding Center (NECC) meningitis outbreak, in which contaminated compounded steroid injections caused over 750 fungal meningitis infections and 64 deaths. DQSA created two compounding categories under the Federal Food, Drug, and Cosmetic Act: Section 503A, covering traditional compounding pharmacies regulated by state boards of pharmacy, and Section 503B, establishing a new class of FDA-registered outsourcing facilities that compound drugs under current Good Manufacturing Practice (cGMP). This legislation was the foundational event for the modern peptide compounding framework, defining which entities can compound, what oversight they face, and what documentation is required.

Key points

• DQSA was passed in direct response to the 2012 NECC fungal meningitis outbreak, which killed 64 people and sickened over 750.
• Section 503A restored traditional compounding pharmacy exemptions after the Supreme Court struck down earlier provisions in Thompson v. Western States Medical Center (2002).
• Section 503B created outsourcing facilities that register with the FDA, comply with cGMP, and can compound drugs without patient-specific prescriptions during a shortage.
• The law distinguishes between state-regulated traditional compounding (503A) and federally overseen outsourcing facilities (503B), creating a two-tier compounding system.
• This framework directly governs whether compounded peptides can be legally produced and distributed, and under what conditions.

2016: FDA Establishes 503A/503B Implementation Framework

Following the passage of DQSA in 2013, the FDA spent several years issuing guidance documents and final rules to implement the 503A and 503B framework. In 2016, the FDA finalized key policies defining the conditions under which traditional compounding pharmacies (503A) and outsourcing facilities (503B) operate, including restrictions on bulk drug substances, the requirement that 503A compounding be based on patient-specific prescriptions, and the scope of the 503B exemption permitting office-stock compounding. These implementation rules shaped the regulatory environment in which compounded peptides could be produced, tested, and distributed.

Key points

• The FDA finalized guidance defining the conditions 503A pharmacies must meet to qualify for exemptions, including patient-specific prescriptions and limits on office use.
• 503B outsourcing facilities were required to register with the FDA, report compounded products, and comply with cGMP standards.
• The FDA established rules for the use of bulk drug substances in compounding, creating lists for substances that can be used and substances that present safety risks.
• These policies defined the legal pathways for compounding peptides, with different requirements for traditional pharmacies and outsourcing facilities.
• The 2016 framework remains the primary regulatory structure governing peptide compounding today.

2017–2023: FDA Warning Letters to Peptide Sellers

Beginning in 2017 and continuing through 2023, the FDA issued a series of warning letters to companies selling peptides online, typically marketed as 'research-use-only' (RUO) products. These warning letters cited violations including unapproved new drug claims, improper labeling, marketing drugs without FDA approval, and making therapeutic claims that contradicted the research-use-only positioning. The FDA's position, articulated in its 2018 RUO/IUO labeling guidance, is that the research-use-only designation does not exempt products from enforcement when therapeutic claims, dosing guidance, or human-use marketing is present. These letters established a pattern of enforcement against the online peptide marketplace and clarified the limits of the RUO shield.

Key points

• The FDA issued warning letters to numerous online peptide sellers citing unapproved new drug claims, misbranding, and improper RUO labeling.
• Warning letters cited specific peptides marketed with therapeutic claims, including those for weight loss, injury recovery, and anti-aging.
• The FDA's 2018 RUO/IUO labeling guidance clarified that RUO designations do not exempt products from enforcement if therapeutic claims or human-use marketing is present.
• Companies receiving warning letters were directed to correct violations or face further enforcement action, including seizure, injunction, or civil money penalties.
• These letters signaled that the FDA views the RUO peptide marketplace as within its enforcement jurisdiction, despite sellers' claims to the contrary.

2020–2021: COVID-19 Era — Increased Interest in Thymosin Alpha-1 and LL-37

During the COVID-19 pandemic, interest in immune-modulating peptides — particularly thymosin alpha-1 and LL-37 (cathelicidin) — surged in the alternative medicine and biohacking communities. Thymosin alpha-1, which is approved in over 30 countries (as Zadaxin) for hepatitis B and C and as an immune adjuvant but is not FDA-approved in the United States, drew attention for its potential role in immune regulation during severe viral infection. LL-37, the sole human cathelicidin antimicrobial peptide, was discussed in research circles for its broad-spectrum antimicrobial properties. The increased demand for these peptides through compounding and research-use-only channels coincided with heightened FDA scrutiny of unapproved products marketed for COVID-19.

Key points

• Thymosin alpha-1 is approved in over 30 countries (as Zadaxin by SciClone Pharmaceuticals) but is not FDA-approved in the United States.
• ClinicalTrials.gov lists over 100 interventional studies of thymosin alpha-1 across infectious disease, oncology, and immune support contexts, including COVID-19 trials.
• LL-37 (cathelicidin) is the sole human antimicrobial peptide in the cathelicidin family and is not FDA-approved for any indication; ClinicalTrials.gov shows limited clinical trial activity.
• The pandemic-driven surge in interest in immune peptides occurred alongside the FDA's broader enforcement against unapproved COVID-19 treatments, which included some peptide products.
• Neither thymosin alpha-1 nor LL-37 has FDA approval for any indication in the United States, and the peer-reviewed literature for both is predominantly preclinical or conducted outside the U.S.

2022–2023: GLP-1 Drug Shortage and the Compounded Semaglutide/Tirzepatide Debate

In 2022 and 2023, unprecedented demand for GLP-1 receptor agonists — Ozempic (semaglutide, approved 2017), Wegovy (semaglutide 2.4 mg, approved 2021), Mounjaro (tirzepatide, approved 2022), and Zepbound (tirzepatide for weight management, approved 2023) — led to national drug shortages. The FDA's drug shortage list included semaglutide and tirzepatide products, which triggered the Section 503B compounding exemption allowing outsourcing facilities to compound these drugs during the shortage. This created a surge of compounded GLP-1 products in the market, accompanied by debate about whether compounded versions using different salt forms (e.g., semaglutide sodium) or non-pharmaceutical-grade raw materials were equivalent to the FDA-approved products. Novo Nordisk and Eli Lilly actively pursued legal action against compounding pharmacies and telehealth companies producing compounded versions of their drugs.

Key points

• Semaglutide (Ozempic, approved 2017; Wegovy, approved 2021) and tirzepatide (Mounjaro, approved 2022; Zepbound, approved 2023) experienced national shortages due to unprecedented demand for weight-loss treatment.
• The FDA drug shortage designation triggered Section 503B exemptions allowing outsourcing facilities to compound these drugs during the shortage period.
• Compounded GLP-1 products used various salt forms and raw materials, raising questions about bioequivalence, purity, and safety compared to FDA-approved products.
• Novo Nordisk and Eli Lilly filed lawsuits against compounding pharmacies and telehealth companies producing compounded semaglutide and tirzepatide.
• The shortage exposed a regulatory gap: compounded GLP-1 products entered the market without the same FDA review, testing, and manufacturing standards as approved drugs.

2023–2024: FDA Actions Against Compounded GLP-1 Products

As the GLP-1 shortage continued, the FDA took a series of actions targeting compounded GLP-1 products. The agency issued warning letters and enforcement actions against compounding facilities and telehealth platforms that produced or distributed compounded semaglutide and tirzepatide without meeting 503B requirements, used non-pharmaceutical-grade ingredients, or made unsubstantiated claims. The FDA also addressed the use of semaglutide sodium and semaglutide acetate — salt forms that are not the same as the active ingredient in Ozempic and Wegovy (semaglutide base) — raising concerns about whether these compounded products met the definition of the approved drug. As shortages began to resolve, the 503B compounding exemption narrowed, and the FDA signaled that compounded GLP-1 products would face increasing scrutiny.

Key points

• The FDA issued warning letters to compounding facilities and telehealth platforms producing compounded GLP-1 products that did not meet 503B requirements.
• The FDA raised concerns about compounded products using semaglutide sodium and semaglutide acetate, which are different salt forms from the approved drug substance (semaglutide base).
• As the FDA declared various GLP-1 products as no longer in shortage, the 503B compounding exemption narrowed, restricting the legal basis for compounding these drugs.
• The agency emphasized that compounded GLP-1 products are not FDA-approved and may not have undergone the same safety, efficacy, and quality review as branded drugs.
• This enforcement period established that the shortage exemption for compounding is temporary and conditional, not a permanent pathway for producing copies of approved drugs.

2025–2026: Bulk Substance Risk List Updates and Gram Peptides Warning Letter

In late 2025 through 2026, the FDA continued updating its lists of bulk drug substances for use in compounding, including the list of substances that may present significant safety risks. These lists directly affect which substances — including peptides — can be used by 503A and 503B compounders. On March 31, 2026, the FDA issued a warning letter to Gram Peptides, an online seller of research-use-only peptide products, citing violations related to the marketing and sale of unapproved peptide products. The Gram Peptides warning letter reinforced the FDA's position that the research-use-only label does not exempt sellers from enforcement when products are marketed in ways that imply human use, and it became a notable reference point for the broader RUO peptide marketplace.

Key points

• The FDA's bulk drug substance lists (including the list of substances that may present significant safety risks) determine which peptides can be legally used in compounding by 503A and 503B facilities.
• On March 31, 2026, the FDA issued a warning letter to Gram Peptides, citing the sale of unapproved peptide products marketed as research-use-only.
• The Gram Peptides warning letter reinforced the FDA's position that RUO labeling does not create a regulatory shield when products are marketed with human-use implications.
• Substances placed on the 'significant safety risk' list face restrictions or prohibitions on their use in compounding, which can effectively remove certain peptides from the legal compounding supply chain.
• These actions signal ongoing and escalating FDA attention to the peptide marketplace, particularly the RUO seller ecosystem.

July 2026: PCAC Meeting — BPC-157, TB-500, and Other Peptides Under Review

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet to discuss multiple peptide bulk substances for potential inclusion on the 503A bulks list or the list of substances that present significant safety risks. Among the substances reportedly under review are BPC-157 (body protection compound, a gastric-derived peptide widely used in the fitness and recovery community) and TB-500 (thymosin beta-4, a synthetic version of a naturally occurring peptide used for injury recovery). The PCAC's recommendations inform the FDA's decisions about whether these substances can be used in compounding, whether they require restriction, or whether they should be flagged as presenting safety risks. This meeting represents a significant moment for the peptide compounding landscape, as the regulatory status of several widely used peptides may shift based on the committee's findings.

Key points

• The July 23–24, 2026 PCAC meeting will review multiple peptide bulk substances for their appropriateness for compounding under 503A.
• BPC-157 (body protection compound) and TB-500 (thymosin beta-4) are among the peptides reportedly under review; both are widely used in the fitness and recovery community without FDA approval.
• The PCAC's recommendations inform FDA decisions about which substances can be used by compounding pharmacies and which may be restricted or flagged as safety risks.
• Substances discussed at PCAC meetings may be added to the 503A bulk list (permitting use), the significant-safety-risk list (restricting use), or neither (leaving their status ambiguous).
• This meeting is a live regulatory event; outcomes may affect the legal availability of compounded versions of these peptides going forward.

Patterns and Takeaways from the Timeline

Several patterns emerge from the chronological record of FDA actions related to peptide compounding and the online peptide marketplace. First, the FDA's enforcement authority over compounding was significantly strengthened by DQSA in 2013, creating a two-tier system (503A and 503B) that remains the governing framework. Second, the research-use-only label does not provide a regulatory shield when products are marketed with therapeutic claims, dosing guidance, or human-use implications — the FDA has consistently enforced this position through warning letters. Third, drug shortages can temporarily open compounding pathways (as seen with GLP-1 drugs), but these pathways close when shortages resolve. Fourth, the FDA's bulk substance lists and PCAC recommendations determine which peptides can be legally compounded, and these lists are actively being updated. The overall trajectory is one of increasing regulatory attention to the peptide space, with the July 2026 PCAC meeting representing a potential inflection point.

Key points

• The 2013 DQSA created the modern compounding framework (503A/503B) that governs how and whether peptides can be legally compounded today.
• The FDA has consistently enforced against RUO peptide sellers who make therapeutic claims, with warning letters serving as the primary enforcement tool.
• Drug shortages can temporarily permit compounding of approved drugs (as with GLP-1s), but this is conditional and reverts when the shortage ends.
• The FDA's bulk substance lists and PCAC meetings determine which peptides are eligible for compounding and which may be restricted as safety risks.
• The regulatory landscape for peptides is actively evolving, with the July 2026 PCAC meeting representing a significant upcoming decision point for substances like BPC-157 and TB-500.

Related pages